• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

bausch&lomb

Bausch+Lomb launches $1.4B offering to finance XIIDRA eye drop buy

September 11, 2023 By Sean Whooley

Bausch + Lomb (1)

Bausch + Lomb (NYSE:BLCO) announced today that it launched an offering worth $1.4 billion in new senior secured notes. The company intends to offer the notes, due 2028, and to enter into an incremental term loan facility. Both moves aim to support the financing of the company’s pending acquisition of XIIDRA. Bausch + Lomb expects […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Mergers & Acquisitions, Optical/Ophthalmic, Wall Street Beat Tagged With: bausch&lomb, Novartis

Bausch + Lomb makes another eye drop acquisition

July 6, 2023 By Sean Whooley

Bausch + Lomb (1)

Bausch + Lomb (NYSE:BLCO) announced today that an affiliate purchased the Blink product line from Johnson & Johnson Vision. The over-the-counter Blink product line features eye and contact lens drops, marking another eye care acquisition for Bausch + Lomb. Last week, the company acquired eye drops and a delivery system from Novartis in a deal […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Optical/Ophthalmic Tagged With: bausch&lomb, Johnson & Johnson Vision

Bausch + Lomb acquires XIIDRA eye drops, delivery system from Novartis in $2.5B deal

June 30, 2023 By Sean Whooley

Bausch + Lomb Novartis

Bausch + Lomb (NYSE:BLCO) announced today that it agreed to acquire XIIDRA non-steroid eye drops from Novartis. The company also acquired an investigational medicine and rights to a delivery device for treating dry eye disease (DED). AcuStream, an investigational device that may have the potential to facilitate precise dosing and accurate delivery of certain topical […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Optical/Ophthalmic, Pharmaceuticals Tagged With: bausch&lomb, Novartis

5 top ophthalmic device innovations you need to know

September 27, 2022 By Sean Whooley

Pixabay image of an eye to symbolize ophthalmic device innovations in the medtech medical device industry

Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye. Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic Tagged With: Alcon, bausch&lomb, Clearside Biomedical, Glaukos, Johnson & Johnson, Johnson & Johnson Vision, Second Sight

Bausch + Lomb, Clearside Biomedical launch Xipere in U.S.

March 28, 2022 By Sean Whooley

Bausch_Health_ Clearside Biomedical

Bausch Health’s (NYSE:BHC) Bausch + Lomb and Clearside Biomedical (Nasdaq:CLSD) launched their Xipere product in the U.S. today. Clearside Biomedical designed the Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for treating macular edema associated with uveitis, a form of eye inflammation. Xipere works with Clearside’s proprietary SCS Microinjector to deliver the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Bausch Health, bausch&lomb, Clearside Biomedical

Systemic therapy beats Bausch & Lomb implant in NIH uveitis study

May 8, 2017 By Sarah Faulkner

National Eye Institute

Systemic therapy of corticosteroids and immunosuppressants better preserved vision in patients with uveitis compared to Bausch & Lomb‘s long-lasting corticosteroid intraocular implant in a clinical trial supported by the National Eye Institute, a branch of the National Institutes of Health. In 7 years, visual acuity remained stable in patients receiving systemic therapy and declined by […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Wall Street Beat Tagged With: bausch&lomb, National Institutes of Health

Sanofi promotes Sibold to exec VP of Sanofi Genzyme | Personnel Moves – April 13, 2017

April 17, 2017 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) said at the start of April that it promoted Bill Sibold to exec VP of Sanofi Genzyme, effective July 1, 2017. Sibold succeeds Dr. David Meeker, who is slated to leave the company at the end of June. Sibold is the head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization. He […]

Pages: Page 1 Page 2

Filed Under: Drug-Device Combinations, Featured, Personnel, Wall Street Beat Tagged With: Abbott Laboratories, bausch&lomb, Biogen Idec, Bristol-Myers Squibb Co., Gerresheimer AG, GlucoMe, Mylan, Ocular Therapeutix, Pulmatrix Inc., Sanofi-Aventis

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS